Floatz logo

Droxidopa

Orthostatic Hypotension

Alberto Espay, MD, MScSmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Orthostatic Hypotension cohort.

Asset / SponsorPhaseRating
Midodrine
Vanderbilt University Medical Center
Phase 2BB
LEVODOPA
University of Utah
Phase 2/3B
Astragalus
Fujian Medical University Union Hospital
Phase 2CCC
DOMPERIDONE
Royal Brisbane and Women's Hospital
Phase 1CC
FLUDROCORTISONE
Royal Brisbane and Women's Hospital
Phase 1CC
Ampreloxetine
Theravance Biopharma
Phase 2CC
TRIMETAPHAN
Vanderbilt University
Phase 1CC

Same molecule, other indications

Droxidopa is also rated in:

primary orthostatic hypotensionDormant
BBB
Indicative ·
76 / 100
View asset →
pure autonomic failureDormant
BB
Indicative ·
68 / 100
View asset →
multiple system atrophyDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →